Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis | Chronic Kidney Disease | JAMA Network Open | JAMA Network
[Skip to Navigation]
Sign In
Figure 1.  Forest Plots of Immunogenicity Rates
Forest Plots of Immunogenicity Rates
Figure 2.  Forest Plots of Immunogenicity Rates By Vaccine Protocol Status
Forest Plots of Immunogenicity Rates By Vaccine Protocol Status
Figure 3.  Association of Diabetes Prevalence and Immunogenicity Rates in the SARS-CoV-2–Naive Dialysis Population With Complete Vaccine Protocol
Association of Diabetes Prevalence and Immunogenicity Rates in the SARS-CoV-2–Naive Dialysis Population With Complete Vaccine Protocol
Table 1.  Characteristics, Vaccine Type, and Vaccine Protocols of Included Studies
Characteristics, Vaccine Type, and Vaccine Protocols of Included Studies
Table 2.  Outcomes of the Included Studies
Outcomes of the Included Studies
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Views 5,629
    Citations 0
    Original Investigation
    October 28, 2021

    Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease: A Systematic Review and Meta-analysis

    Author Affiliations
    • 1Department of Nephrology, Chang Gung Memorial Hospital, Linkou, Taiwan
    • 2Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Linkou, Taiwan
    JAMA Netw Open. 2021;4(10):e2131749. doi:10.1001/jamanetworkopen.2021.31749
    Key Points

    Question  What are the immunogenicity rates in people with end-stage kidney disease receiving SARS-CoV-2 vaccines?

    Findings  This systematic review and meta-analysis of 32 studies found that patients receiving dialysis had lower immunogenicity rates after first and second vaccine doses than those not receiving dialysis. Prevalence of diabetes had an inverse linear association with immunogenicity rate.

    Meaning  These findings suggest that the immunogenicity rate after vaccination was lower in patients receiving dialysis and that diabetes might be a risk factor for nonresponse to vaccination.


    Importance  Adults receiving dialysis treatment have a higher likelihood of death when infected with SARS-CoV-2 than adults not receiving dialysis treatment. To date, the immune response of people receiving dialysis after SARS-CoV-2 vaccination has not been systematically discussed.

    Objective  To assess immunogenicity rates in people with end-stage kidney disease (ESKD) receiving SARS-CoV-2 vaccines, explore postvaccination potential risk factors for nonresponse, and assess whether receiving dialysis is associated with different antibody response rates compared with the nondialysis population.

    Data Sources  This systematic review and meta-analysis used articles from PubMed, Medline, and Embase published before July 30, 2021, as well as articles in the medRxiv preprint server.

    Study Selection  Studies that evaluated the immunogenicity rate according to the postvaccine antibody response rate in patients with ESKD receiving dialysis were selected.

    Data Extraction and Synthesis  The meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. A random-effects model was used. Two independent reviewers conducted the literature search and extracted the data.

    Main Outcomes and Measures  The primary outcome was the pooled antibody postvaccine response rates in individuals with ESKD. The secondary outcomes were pooled response rates in individuals receiving and not receiving dialysis. Subgroup analysis and meta-regression were conducted to identify the sources of heterogeneity.

    Results  A total of 32 studies were included. The overall immunogenicity rate of the dialysis group was 86% (95% CI, 81%-89%). Meta-regression showed a significant difference was detected in the postvaccine response rate on the basis of prevalence of diabetes (regression coefficient, −0.06; 95% CI, −0.10 to −0.02; P = .004). Compared with nondialysis controls, patients in the dialysis group had a lower response rate after the first (relative risk [RR], 0.61; 95% CI, 0.47-0.79; I2 = 70.2%) and second (RR, 0.88; 95% CI, 0.82-0.93; I2 = 72.2%) doses, with statistically significantly increased RR between first and second doses (P = .007).

    Conclusions and Relevance  These findings suggest that the immunogenicity rate among patients receiving dialysis was 41% after the first dose and 89% after the second dose. Diabetes might be a risk factor for nonresponse in the dialysis population. Patients receiving dialysis had a poorer antibody response rate than did individuals not receiving dialysis, particularly after the first dose.


    Adults receiving dialysis have a higher mortality risk when infected with SARS-CoV-2 than do adults not receiving dialysis.1,2 Because most clinical trials have not included people with end-stage kidney disease (ESKD),3,4 immunogenicity rates are instead assessed to determine the efficacy of SARS-CoV-2 vaccines in this population. Several studies have reported that antibody response rates vary depending on vaccination protocols, vaccine types, and populations. Old age or use of immunosuppression medication have been identified as risk factors for vaccine nonresponse.5-8 However, the immunogenicity rates of patients receiving dialysis have not yet been systematically reviewed, to our knowledge.

    In this study, immunogenicity rates among people with ESKD after receiving SARS-CoV-2 vaccines were investigated, as were potential risk factors for vaccine nonresponse and significant differences in antibody response rates between adults receiving dialysis and those not receiving dialysis.

    Literature Search Strategy and Eligibility Criteria

    This systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Regarding the systematic review, the PubMed, Embase, and Medline databases were searched for relevant articles published between January 1, 2020 and July 30, 2021 (eTable 1 in the Supplement). Keywords used to retrieve preprint articles from the medRxiv server included dialysis, end-stage renal disease, SARS-CoV-2 vaccine, ChAdOx1 nCoV-19, Oxford–AstraZeneca, mRNA vaccines, BNT162b2, and mRNA-1273.

    We included studies on people with ESKD receiving hemodialysis or peritoneal dialysis. Other inclusion criteria were studies examining adult populations and those that reported postvaccination antibody response rates. Our search was limited to clinical trials, letters, commentaries, and preprint articles published in English after 2019. Two independent reviewers (J.-J.C. and C.-H.C.) independently assessed the titles, abstracts, and full texts (if necessary) of each publication.

    Outcome Measurement and Data Extraction

    The primary outcome was postvaccination immunogenicity rates among patients with ESKD. Overall antibody response rates were analyzed if data on the neutralizing antibody were available. Otherwise, we extracted the response rates in the following sequence: anti-SARS-CoV-2 spike receptor-binding domain protein or anti-spike protein. Two reviewers (J.-J.C. and C.-H.C.) conducted the data extraction independently. We also extracted relevant variables, including the patients’ mean age, sex, dialysis vintage, diabetes diagnosis, type of vaccine received, kidney replacement modality, vaccination protocol (total doses and the interval between the first and second doses), and length of follow-up period. Studies that did and did not exclude prior SARS-CoV-2 infection were included. Any disagreements were resolved through consensus with a third author (T.H.L.).

    The secondary outcome was the immunogenicity rates of patients with ESKD receiving dialysis compared with those of people without ESKD, not receiving dialysis. In most studies, the control group included health care workers in a dialysis facility.

    Risk of Bias

    The quality of the cohort studies was assessed by 2 independent reviewers (J.-J.C. and C.-H.C.) using the Newcastle-Ottawa scale (NOS), which allocates a maximum of 9 points for 3 major domains: quality of the selection, comparability, and the outcome of study populations. Studies reporting scores of 7 to 9 points were considered to have low risk; 4 to 6 points, moderate risk; and less than 4 points, high risk of bias.9

    Statistical Analysis

    The primary outcome, the proportions of postvaccination immunogenicity in the patients receiving dialysis, for the included studies was pooled using the DerSimonian-Laird random-effects model. The I2 statistic was used to assess the heterogeneity of the pooled estimate, where a value greater than 0.5 was considered substantially heterogenous. To explore the potential source of heterogeneity, we conducted several subgroup analyses using mixed effects models, including (1) incomplete, complete, or booster vaccination protocols; (2) populations with prior SARS-CoV-2 infection or without prior SARS-CoV-2 infection; and (3) kidney replacement therapy modality, including hemodialysis or peritoneal dialysis. We also performed univariate random-effects meta-regression analysis using the following study-level explanatory variables: mean age, the proportion of women, mean dialysis vintage, and the prevalence of diabetes. Of note, all subgroup analysis (except regarding SARS-CoV-2 infection status) and meta-regression were performed in the selected studies that enrolled SARS-CoV-2–naive populations with complete vaccine protocols. In addition, the preprinted articles were excluded to assess the robustness of the overall result in sensitivity analysis.

    The secondary outcome, immunogenicity rates of patients receiving dialysis compared with individuals not receiving dialysis, was summarized as the pooled relative risk using the DerSimonian-Laird random-effects model. The pooled estimate of secondary outcomes between the studies with complete and those with incomplete protocols was further compared using the mixed effects model. Finally, using the overall analysis of primary outcome, publication bias was assessed using visual check by funnel plot and formal statistical test by the Egger intercept test. All analyses were conducted using Comprehensive Meta-Analysis Software version 3.3.070 (Biostat). P values were 2-sided, and statistical significance was set at P < .05. Data were analyzed in August 2021.

    Literature Search

    We identified 104 potentially eligible studies from the PubMed, 335 potentially eligible studies from Embase, and 46 potentially eligible studies from Medline databases. From the medRxiv server, 184 potentially eligible preprint studies were identified. After the titles and abstracts were screened, the full texts were reviewed to further determine study eligibility. After the exclusion of irrelevant studies, including studies not addressing the outcome of interest and studies only based on ESKD with kidney transplant population, 32 studies,5-8,10-31 including 6 preprint articles,32-37 were included in the meta-analysis (eFigure 1 in the Supplement). The extracted data are summarized in Table 1 and Table 2.

    Study Characteristics

    A total of 4917 participants were included in this meta-analytic study, and 4 vaccines (JNJ-78436735 [Janssen], mRNA-1273 [Moderna], BNT162b2 [Pfizer-BioNTech], and AZD1222 [AstraZeneca]) were administered. Most participants received the BNT162b2 vaccine. All enrolled participants did not receive a mixture of different SARS-CoV-2 vaccines. Six preprint articles were selected from the medRxiv server and another 5 studies from enrolled studies only reported the immunogenicity rates of patients receiving dialysis who did not complete the vaccination protocol (ie, those who received only 1 dose of the BNT162b, AZD1222, or mRNA-1273 vaccines).7,11-13,37 Other articles reported an antibody response rate after the second dose with or without reporting the response rate after the first dose. Three studies discussed immunogenicity rates after the booster shot.14-16 The mean age of the participants ranged from 60.5 to 76 years (Table 1). Hemodialysis was the predominant kidney replacement therapy modality. Five studies enrolled people receiving mixed peritoneal dialysis and hemodialysis,12,16-18,34 and only 1 study19 enrolled patients only receiving peritoneal dialysis (Table 1). Few studies reported the dialysis adequacy in the enrolled population, and all of them were noted with a Kt/V exceeding 1.3. The mean dialysis vintage varied from 1.7 to 7 years, and all included studies had a low to moderate risk of bias (NOS score: 5-8) (eTable 2 in the Supplement).

    Primary and Secondary Outcomes

    The meta-analysis revealed that the overall immunogenicity rate in patients receiving dialysis was 86% (95% CI, 81%-89%) with high heterogeneity (I2 = 90.6%) (Figure 1A). We also performed meta-analysis to determine whether the antibody response rate was significantly different between patients receiving dialysis and individuals not receiving dialysis. Immunogenicity rates after the first dose (relative risk [RR], 0.61; 95% CI, 0.47-0.79; I2 = 70.2%) and second dose (RR, 0.88; 95% CI, 0.82-0.93; I2 = 72.2%) were significantly lower in the dialysis group than in the control group. Noticeably, the lower response rate of the patients receiving dialysis, relative to those not receiving dialysis, was less apparent in the second dose than that in the first dose (P = .007) (Figure 1B).

    Sensitivity Analysis

    We conducted a sensitivity analysis that excluded the preprinted and unpublished articles. The result was highly consistent to that of the primary analysis, with the pooled immunogenicity rate of 85% (95% CI, 79%-90%) along with high heterogeneity (I2 = 89.8%) (eFigure 2 in the Supplement).

    Subgroup Analysis and Meta-regression

    Subgroup analysis was performed to identify the potential source of heterogeneity. The response rate was the lowest in patients without complete vaccination protocols (41%; 95% CI, 32%-52%; I2 = 87.3%), followed by in those with complete vaccination protocols (89%; 95% CI, 85%-91%; I2 = 66.7%) and was highest in those with third booster vaccine protocols (94%; 95% CI, 86%-97%; I2 = 50.1%; P < .001) Figure 2A). The postvaccination immune response rates of participants with a history of SARS-CoV-2 infection was significantly higher than those without such a history (96%; 95% CI, 95%-99%; vs 86%; 95% CI, 81%-89%; P = .02; Figure 2B). No significant difference in the response rate was detected between hemodialysis and peritoneal dialysis (87%; 95% CI, 83%-90%; vs 94%; 95% CI, 84%-98%; P = .15) (eFigure 3 in the Supplement).

    The meta-regression analysis showed that a higher prevalence of diabetes was significantly correlated with a lower immune response rate (regression coefficient, −0.06; 95% CI, −0.10 to −0.02; P = .004) (Figure 3). No significant associations between mean age, proportion of women, dialysis vintage, and response rate were observed (eFigures 4-6 in the Supplement).

    Publication Bias

    The funnel plot revealed some asymmetry, which implied that there was a problem of publication bias (eFigure 7 in the Supplement). The Egger test also revealed a significant result (P = .04) which indicated the existence of publication bias in this meta-analysis.


    This systematic review and meta-analysis found 4 notable results. First, the overall immunogenicity rate in the analyzed studies was 86%. Second, the immunogenicity rates after the first dose and the second dose were both significantly lower in individuals receiving dialysis than in those not receiving dialysis, and this difference was smaller after 2 doses. Third, the immunogenicity rates were significantly higher in those with a prior history of SARS-CoV-2 infection, and the immunogenicity rates increased significantly after the second and third booster dose compared with the immunogenicity rates observed after the first dose. Furthermore, a significant inverse association between diabetes prevalence and response rate was noted.

    Several studies have reported that people receiving dialysis have lower immune response rates after SARS-CoV-2 vaccination than do those not receiving dialysis.10-12,20-25,30,36 This result is inconsistent with the previous studies that have demonstrated that patients with ESKD who are receiving dialysis have a lower immune response to the hepatitis B virus vaccine compared with the general population.38,39 Lower mean antibody titer and poor T-cell immune responses relative to individuals not receiving dialysis were also observed in those receiving dialysis.23 A study by Speer et al23 has indicated that patients receiving dialysis had not only a lower probability of producing antispike antibodies but also a lower probability of producing overthreshold levels of neutralizing antibodies. In this study, we found that immunogenicity rates after the first and the second dose were lower among individuals receiving dialysis than in those not receiving dialysis. Moreover, this difference in response rates became significantly smaller after the second dose. Our findings suggest that in the dialysis population, scheduled, earlier second vaccination, not a delayed second COVID-19 vaccine dose protocol, may be better.

    Risk factors for nonresponse among patients receiving dialysis included old age,6-8 nonresponse to hepatitis B vaccination,10 low serum albumin levels,10,17 dialysis inadequacy,10 and use of immunosuppressants.16,26 The use of old age as a risk factor for vaccine nonresponse was inconsistent in the reviewed studies, and some trials did not determine that old age was a significant risk factor for poor response.16,23 Speer et al23 noted an inverse linear association between age and immune response rate in a healthy control group and no age-related differences in neutralizing antibody production.20 In this study, we detected no inverse linear association between age and immunogenicity rates.

    Diabetes was considered a risk factor for immune system dysfunction and nonresponse after vaccination according to previous studies.40,41 The combination of diabetes and ESKD was demonstrated as a risk factor for hyporesponsiveness after hepatitis B vaccination.42,43 In this study, we found that prevalence of diabetes was inversely associated with immune response rate after SARS-CoV-2 vaccination. Further larger, well-designed studies are needed to examine this association.


    Our study has several limitations. First, in the examined studies, vaccination efficacy was based on the immunobridging approach, which relies on humoral immunity. However, after vaccination, increased intracellular production of S protein also primes both CD8+ and CD4+ T cells to differentiate into effector and memory subsets of inflammatory and cytotoxic mediators and CD4+ T helper cells, which promote B cell differentiation into antibody-secreting plasma cells. The ability of antibodies to neutralize the mutated virus might decrease, but cellular immunity remains activated during infection by the mutated virus.44 However, because the assessment of cellular immunity was not well established, the comparison conducted in this meta-analysis cannot completely reflect the protective effect of vaccination. Furthermore, some studies examining mixed SARS-CoV-2 vaccines did report the immunogenicity by measuring the antibody levels or T cell reactivity by interferon γ release assay.45,46 Real-world evidence of mixed vaccines protocols is lacking. Ethical concerns are challenging the use of placebos in phase 3 randomized clinical trials on vaccines. Therefore, immunobridging research provides a comparable platform for various vaccines. Second, we only evaluated the immune response rate after the administration of the third booster dose. A study by Frantzen et al15 found increases in the antibody levels of patients who had received the booster shot. Further studies are required to examine the immune response and clinical protective effect of the booster dose in patients receiving dialysis.


    This systematic review and meta-analysis found that patients with ESKD had a pooled postvaccine immune response rate of 86%. Compared with the nondialysis group, patients receiving dialysis had a lower probability of producing an antibody response after receiving the first dose and second dose of a COVID-19 vaccine. Furthermore, this difference between nondialysis and dialysis populations became statistically smaller after the second dose. Scheduling the second vaccine dose without delay might be preferable in patients receiving dialysis. Prevalence of diabetes had an inverse linear association with the immune response rate. Further investigations of immune response and side effects of SARS-CoV-2 vaccines in patients receiving dialysis, as well as the benefits and real world clinical efficacy of different vaccine protocols, different types of vaccine, are warranted.

    Back to top
    Article Information

    Accepted for Publication: August 27, 2021.

    Published: October 28, 2021. doi:10.1001/jamanetworkopen.2021.31749

    Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Chen JJ et al. JAMA Network Open.

    Corresponding Author: Chih-Hsiang Chang, MD, Department of Nephrology, Linkou Chang Gung Memorial Hospital, Taipei, Taiwan (

    Author Contributions: Drs Chang and Chen had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

    Concept and design: Chen, T.H. Lee, Tian, Chang.

    Acquisition, analysis, or interpretation of data: Chen, C.-C. Lee, Fan, Chang.

    Drafting of the manuscript: Chen.

    Critical revision of the manuscript for important intellectual content: T.H. Lee, Tian, C.-C. Lee, Fan, Chang.

    Statistical analysis: Chen, Fan, Chang.

    Obtained funding: Fan, Chang.

    Administrative, technical, or material support: T.H. Lee, Fan, Chang.

    Supervision: Tian, C.-C. Lee.

    Conflict of Interest Disclosures: None reported.

    Funding/Support: This study was supported by grant No. CMRPG5K0141 from Chang Gung Memorial Hospital, and Dr Chang was supported by grant No. 109-2314-B-182A-124 from the Ministry of Science and Technology.

    Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

    Ng  JH, Hirsch  JS, Wanchoo  R,  et al; Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium.  Outcomes of patients with end-stage kidney disease hospitalized with COVID-19.   Kidney Int. 2020;98(6):1530-1539. doi:10.1016/j.kint.2020.07.030PubMedGoogle ScholarCrossref
    Jung  HY, Lim  JH, Kang  SH,  et al.  Outcomes of COVID-19 among patients on in-center hemodialysis: an experience from the epicenter in South Korea.   J Clin Med. 2020;9(6):E1688. doi:10.3390/jcm9061688PubMedGoogle Scholar
    Chewcharat  A, Chang  YT, Sise  ME, Bhattacharyya  RP, Murray  MB, Nigwekar  SU.  Phase-3 randomized controlled trials on exclusion of participants with kidney disease in COVID-19.   Kidney Int Rep. 2021;6(1):196-199. doi:10.1016/j.ekir.2020.10.010PubMedGoogle ScholarCrossref
    Ikizler  TA, Coates  PT, Rovin  BH, Ronco  P.  Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy.   Kidney Int. 2021;99(6):1275-1279. doi:10.1016/j.kint.2021.04.007PubMedGoogle ScholarCrossref
    Yi  SG, Knight  RJ, Graviss  EA,  et al.  Kidney transplant recipients rarely show an early antibody response following the first COVID-19 vaccine administration.   Transplantation. 2021;105(7):e72-e73. doi:10.1097/TP.0000000000003764PubMedGoogle ScholarCrossref
    Attias  P, Sakhi  H, Rieu  P,  et al.  Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients.   Kidney Int. 2021;99(6):1490-1492. doi:10.1016/j.kint.2021.04.009PubMedGoogle ScholarCrossref
    Billany  RE, Selvaskandan  H, Adenwalla  SF,  et al.  Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms.   Kidney Int. 2021;99(6):1492-1494. doi:10.1016/j.kint.2021.04.008PubMedGoogle ScholarCrossref
    Broseta  JJ, Rodríguez-Espinosa  D, Rodríguez  N,  et al.  Humoral and cellular responses to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccines administered to hemodialysis patients.   Am J Kidney Dis. 2021;S0272-6386(21)00689-2. doi:10.1053/j.ajkd.2021.06.002PubMedGoogle Scholar
    Wells  G, Shea  B, O’Connell  D,  et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed September 28, 2021.
    Danthu  C, Hantz  S, Dahlem  A,  et al.  Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients.   J Am Soc Nephrol. 2021;ASN.2021040490. doi:10.1681/ASN.2021040490PubMedGoogle Scholar
    Goupil  R, Benlarbi  M, Beaubien-Souligny  W,  et al; Réseau Rénal Québécois (Quebec Renal Network) COVID-19 Study Investigators.  Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.   CMAJ. 2021;193(22):E793-E800. doi:10.1503/cmaj.210673PubMedGoogle ScholarCrossref
    Lesny  P, Anderson  M, Cloherty  G,  et al.  Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study.   J Nephrol. 2021;34(4):975-983. doi:10.1007/s40620-021-01076-0PubMedGoogle ScholarCrossref
    Torreggiani  M, Blanchi  S, Fois  A, Fessi  H, Piccoli  GB.  Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won.   Kidney Int. 2021;99(6):1494-1496. doi:10.1016/j.kint.2021.04.010PubMedGoogle ScholarCrossref
    Ducloux  D, Colladant  M, Chabannes  M, Yannaraki  M, Courivaud  C.  Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis.   Kidney Int. 2021;100(3):702-704. doi:10.1016/j.kint.2021.06.025PubMedGoogle ScholarCrossref
    Frantzen  L, Thibeaut  S, Moussi-Frances  J,  et al.  COVID-19 vaccination in haemodialysis patients: good things come in threes….   Nephrol Dial Transplant. 2021;gfab224. doi:10.1093/ndt/gfab224PubMedGoogle Scholar
    Longlune  N, Nogier  MB, Miedougé  M,  et al.  High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients.   Nephrol Dial Transplant. 2021;gfab193. doi:10.1093/ndt/gfab193PubMedGoogle Scholar
    Agur  T, Ben-Dor  N, Goldman  S,  et al.  Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study.   Nephrol Dial Transplant. 2021;gfab155. doi:10.1093/ndt/gfab155PubMedGoogle Scholar
    Schrezenmeier  E, Bergfeld  L, Hillus  D,  et al.  Immunogenicity of COVID-19 tozinameran vaccination in patients on chronic dialysis.   Front Immunol. 2021;12:690698. doi:10.3389/fimmu.2021.690698PubMedGoogle Scholar
    Rodríguez-Espinosa  D, Broseta  JJ, Maduell  F, Bedini  JL, Vera  M.  Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients.   Kidney Int. 2021;100(2):476-477. doi:10.1016/j.kint.2021.05.018PubMedGoogle ScholarCrossref
    Grupper  A, Sharon  N, Finn  T,  et al.  Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis.   Clin J Am Soc Nephrol. 2021;CJN.03500321. doi:10.2215/CJN.03500321PubMedGoogle Scholar
    Rincon-Arevalo  H, Choi  M, Stefanski  AL,  et al.  Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients.   Sci Immunol. 2021;6(60):eabj1031. doi:10.1126/sciimmunol.abj1031PubMedGoogle Scholar
    Jahn  M, Korth  J, Dorsch  O,  et al.  Humoral response to SARS-CoV-2-vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis.   Vaccines (Basel). 2021;9(4):360. doi:10.3390/vaccines9040360PubMedGoogle ScholarCrossref
    Speer  C, Göth  D, Benning  L,  et al.  Early humoral responses of hemodialysis patients after COVID-19 vaccination with BNT162b2.   Clin J Am Soc Nephrol. 2021;CJN.03700321. doi:10.2215/CJN.03700321PubMedGoogle Scholar
    Yanay  NB, Freiman  S, Shapira  M,  et al.  Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients.   Kidney Int. 2021;99(6):1496-1498. doi:10.1016/j.kint.2021.04.006PubMedGoogle ScholarCrossref
    Sattler  A, Schrezenmeier  E, Weber  UA,  et al.  Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients.   J Clin Invest. 2021;131(14):150175. doi:10.1172/JCI150175PubMedGoogle Scholar
    Bertrand  D, Hamzaoui  M, Lemée  V,  et al.  Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients.   J Am Soc Nephrol. 2021;ASN.2021040480. doi:10.1681/ASN.2021040480PubMedGoogle Scholar
    Chan  L, Fuca  N, Zeldis  E, Campbell  KN, Shaikh  A.  Antibody response to mRNA-1273 SARS-CoV-2 vaccine in hemodialysis patients with and without prior COVID-19.   Clin J Am Soc Nephrol. 2021;16(8):1258-1260. doi:10.2215/CJN.04080321PubMedGoogle ScholarCrossref
    Frantzen  L, Cavaille  G, Thibeaut  S, El-Haik  Y.  Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a hemodialysis cohort.   Nephrol Dial Transplant. 2021;gfab165. doi:10.1093/ndt/gfab165PubMedGoogle Scholar
    Lacson  E, Argyropoulos  C, Manley  H,  et al.  Immunogenicity of SARS-CoV-2 Vaccine in Dialysis.   J Am Soc Nephrol. Published online August 4, 2021. doi:10.1681/ASN.2021040432 PubMedGoogle Scholar
    Simon  B, Rubey  H, Treipl  A,  et al.  Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls.   Nephrol Dial Transplant. 2021;gfab179. doi:10.1093/ndt/gfab179PubMedGoogle Scholar
    Zitt  E, Davidovic  T, Schimpf  J,  et al.  The safety and immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 vaccine in hemodialysis patients.   Front Immunol. 2021;12:704773. doi:10.3389/fimmu.2021.704773PubMedGoogle Scholar
    Anand  S, Montez-Rath  ME, Han  J,  et al  Antibody response to COVID-19 vaccination in patients receiving dialysis.   medRxiv. Preprint posted online May 12, 2021. doi:10.1101/2021.05.06.21256768Google Scholar
    Clarke  CL, Martin  P, Gleeson  S,  et al  Comparison of immunogenicity between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in a large haemodialysis population.   medRxiv. Preprint posted online July 14, 2021. doi:10.1101/2021.07.09.21260089Google Scholar
    Duarte  R, Roldão  M, Figueiredo  C,  et al  Humoral response to BNT162b2 mRNA COVID-19 vaccine in peritoneal and hemodialysis patients: a comparative study.   medRxiv. Preprint posted online June 15, 2021. doi:10.1101/2021.06.14.21258113Google Scholar
    Strengert  M, Becker  M, Ramos  GM,  et al  Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on hemodialysis.   medRxiv. Preprint posted online May 29, 2021. doi:10.1101/2021.05.26.21257860Google Scholar
    Weigert  A, Bergman  M-L, Gonçalves  L,  et al  Longitudinal analysis of antibody responses to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis.   medRxiv. Preprint posted online July 22, 2021. doi:10.1101/2021.07.20.21260849Google Scholar
    Yau  K, Abe  KT, Naimark  D,  et al  The humoral response to the BNT162b2 vaccine in hemodialysis patients.   medRxiv. Preprint posted online May 27, 2021. doi:10.1101/2021.05.24.21257425Google Scholar
    Gasim  GI, Bella  A, Adam  I.  Immune response to hepatitis B vaccine among patients on hemodialysis.   World J Hepatol. 2015;7(2):270-275. doi:10.4254/wjh.v7.i2.270PubMedGoogle ScholarCrossref
    Asan  A, Demirhan  H, Sorkun  HC,  et al.  Factors affecting responsiveness to hepatitis B immunization in dialysis patients.   Int Urol Nephrol. 2017;49(10):1845-1850. doi:10.1007/s11255-017-1616-9PubMedGoogle ScholarCrossref
    Berbudi  A, Rahmadika  N, Tjahjadi  AI, Ruslami  R.  Type 2 diabetes and its impact on the immune system.   Curr Diabetes Rev. 2020;16(5):442-449. doi:10.2174/1573399815666191024085838PubMedGoogle ScholarCrossref
    Saco  TV, Strauss  AT, Ledford  DK.  Hepatitis B vaccine nonresponders: possible mechanisms and solutions.   Ann Allergy Asthma Immunol. 2018;121(3):320-327. doi:10.1016/j.anai.2018.03.017PubMedGoogle ScholarCrossref
    Fabrizi  F, Dixit  V, Messa  P, Martin  P.  Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants: a meta-analysis of randomized trials.   Vaccine. 2012;30(13):2295-2300. doi:10.1016/j.vaccine.2012.01.064PubMedGoogle ScholarCrossref
    Udomkarnjananun  S, Takkavatakarn  K, Praditpornsilpa  K,  et al.  Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis.   J Nephrol. 2020;33(2):343-354. doi:10.1007/s40620-019-00668-1PubMedGoogle ScholarCrossref
    Geers  D, Shamier  MC, Bogers  S,  et al.  SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.   Sci Immunol. 2021;6(59):eabj1750. doi:10.1126/sciimmunol.abj1750PubMedGoogle Scholar
    Ledford  H.  Could mixing COVID vaccines boost immune response?   Nature. 2021;590(7846):375-376. doi:10.1038/d41586-021-00315-5PubMedGoogle ScholarCrossref
    Hillus  D, Schwarz  T, Tober-Lau  P,  et al; EICOV/COVIM Study Group.  Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.   Lancet Respir Med. 2021;S2213-2600(21)00357-X. doi:10.1016/S2213-2600(21)00357-XPubMedGoogle Scholar